Source: GlobeNewswire (H1 press release) — 2026-08-04
Summary
H1 announced a strategic partnership with Novo Nordisk to build proprietary AI-ready data and AI-powered clinical development workflows, aimed at speeding the path from drug discovery to approval. As part of the deal, H1 acquires rights to further develop StudyHub, an internal digital and AI-enabled clinical development platform originally built by Novo Nordisk, with plans to commercialize it as an industry-wide tool for trial site selection and study management.
Key Takeaways
- H1 will combine its global "Doctor Graph" and AI-ready healthcare datasets with Novo Nordisk's clinical operations to optimize protocol design, site selection, and patient enrollment.
- StudyHub moves from an internal Novo Nordisk tool to a platform H1 plans to commercialize more broadly across the pharmaceutical industry.
- The stated goal is reducing clinical development timelines by giving trial teams more informed, earlier decisions on site selection and enrollment — no specific percentage or day-count reduction was disclosed in the release.
- This is part of a broader trend of major pharma companies partnering with (or acquiring stakes in) health-data/AI vendors to modernize trial operations rather than building this infrastructure entirely in-house.